4D Molecular Therapeutics, Inc. - Common Stock — 四半期キャッシュフロー (NASDAQ:FDMT) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

総資産 560.38 M515.73 M473.64 M423.98 M566.71 M512.9 M 負債合計 49.78 M46.01 M52.75 M55 M61.05 M61.07 M 純資産合計 510.61 M469.72 M420.89 M368.98 M505.66 M451.84 M 負債および純資産合計 560.38 M515.73 M473.64 M423.98 M566.71 M512.9 M 有利子負債合計 —————— 純負債 ——————

ニュース

4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:FDMT) 2026-01-19

RBCキャピタル、4Dモレキュラー株に対し「アウトパフォーム」評価を32ドルで維持

RBC Capital reiterates Outperform rating on 4D Molecular stock at $32

4Dモレキュラー・セラピューティクスのアシュー・グプタ氏、FDMTの株式を330万ドル分売却

Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)